New scanner aims to spot breast Cancer's true reach

NCT ID NCT05659797

Recruiting now Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new imaging device that combines two types of breast scans to see how well it detects estrogen-receptor-positive breast cancer. Up to 20 women with newly diagnosed breast cancer will receive an injection of a radioactive tracer and then be scanned. The results will not be used to guide treatment, but will help researchers understand if this method could improve future cancer imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Fluoroestradiol (FES)
What this could lead to: If successful, this imaging method could help doctors see the full extent of estrogen-receptor-positive breast cancer more clearly, potentially guiding better treatment decisions.
What could go wrong: This is a very early pilot study with only 20 people. It is not designed to change treatment yet, and the imaging results are not used for patient care. The device may not prove better than standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.